Category Archives: Yahoo

TipRanks

Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Fridays release of economic data showing strong manufacturing activity provided a boost that pared back the market losses somewhat. The recent earnings season also gave reason for optimism the S&P listed companies, collectively, reported 46% year-over-year earnings gains in Q1, compared to the 20% expected. Goldman Sachs strategist David Kostin sees the generally positive macro data providing support for equities in an uncertain market environment. The combination of global reopening, elevated consumer savings, and strong corporate operating leverage will drive sharp recoveries in both economic and earnings growth... U.S. equities will continue to appreciate, albeit at a slower pace than has characterized the past 12 months equities will remain attractive relative to cash and bonds, Kostin noted. Taking this into consideration, our attention turned to three stocks that Goldman Sachs thinks have outsized growth prospects, with the firms analysts forecasting over 100% upside potential for each. Using TipRanks database, we found out that the rest of the Street is also on board, as each boasts a Strong Buy consensus rating. Rain Therapeutics (RAIN) Well start with a newly public biopharmaceutical company Rain Therapeutics. The company is developing a tumor-agnostic treatment strategy that selects patients based on the underlying genetics rather than the histology of the disease. Rain has two drug candidates in the pipeline, RAIN-32, which is undergoing several clinical trials, and RAD52, which is still in preclinical trial. Taking a closer look at the pipeline, we find that RAIN-32, an MDM2 inhibitor called milademetan, has a Phase 3 trial for WD/DD liposarcoma scheduled to begin in the second half of this year. At the same time, a Phase 2 trial, an MDM2 basket study, is also scheduled for 2H21. Beyond the WD/DD Phase 3 and the Phase 2 Basket study, the company is also looking to initiate another Phase 2 study in intimal sarcoma by early 2022. RAD52, the companys second pipeline candidate, is a novel approach to the treatment of breast, prostate, pancreatic, and ovarian cancers. The drug is still in early research phases, but lead candidate selection for clinical studies is set to begin sometime next year. As mentioned above, Rain is a newly public company; it held its IPO in April of this year. The company put 7,352,941 shares on the American public markets, at $17 each. The IPO raised about $125 million in gross proceeds. Opening coverage of this stock for Goldman Sachs, analyst Graig Suvannavejh writes: While were optimistic on RAIN-32s prospects in LPS, the revenue opportunity appears modest, as we project peak risk-unadj./adj. sales of $612mn/$428mn (assumes 70% POS), given just c.3K in US annual incidence. That said, our enthusiasm for RAIN also rests on RAIN-32s potential beyond LPS, including in intimal sarcoma (an ultra orphan cancer), and also MDM2-amplified solid tumors, which we see as a substantial market opportunity. Across these three, we project $2.2bn/$859mn in peak yr risk unadj./adj. sales in the US/EU5, with other future indications for RAIN-32 (trials to start in 2022) and also a preclinical RAD52 program (a synthetic lethality play) representing upside potential to our forecasts. In line with his bullish stance, Suvannavejh rates RAIN a Buy, and his $56 price target implies room for a stunning 252% upside potential in the next 12 months. (To watch Suvannavejhs track record, click here) Turning now to the rest of the Street, other analysts echo Suvannavejh's sentiment. As only Buy recommendations have been published in the last three months, RAIN earns a Strong Buy analyst consensus. With the average price target clocking in at $33.75, shares could soar 112% from current levels. (See RAIN stock analysis on TipRanks) Relmada Therapeutics (RLMD) The next stock on Goldman Sachs's radar, Relmada Therapeutics, is a clinical-stage pharmaceutical firm, which focuses on issues of the central nervous system. REL-1017, the companys prime pipeline candidate, is a novel NMDA receptor channel blocker under development as a treatment for major depressive disorder. Mental health is a major segment of the pharmaceutical industry, and the antidepressant piece of the mental health pie is expected to exceed $18.5 billion by 2027. Relmada started RELIANCE I, the first pivotal trial of REL-1017, in December of last year, testing the drug as an adjunctive treatment for major depression. By this past April, two additional studies, RELIANCE II and RELIANCE-OPS were underway. All three are now ongoing, and a fourth, Phase 1, study of REL-1017 as a monotherapy is set to begin in the first half of this year. Top-line data from the two pivotal studies is scheduled for release in 1H22. Goldman Sachs analyst Andrea Tan covers this stock, and she gives it a Buy rating along with a $78 price target that implies a 103% upside over the next 12 months. (To watch Tans track record, click here) We note a string of key events in 2021+ that could drive value inflection: (1) human abuse potential (HAP) study against positive control oxycodone in 2Q21 and ketamine in 2H21, where we see the market as pricing in too much risk of a negative outcome (see scenario analysis within); (2) topline data for monotherapy REL-1017 in 4Q21; and (3) topline pivotal data in adjunctive MDD (GSe peak sales of $2.5bn in 2033) in 1H22 with NDA submission to follow thereafter, all of which we are constructive on given the differentiated profile demonstrating rapid onset of action, enhanced efficacy, and good tolerability to-date, Tan opined. What does the rest of the Street have to say? 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $67.67 average price target, shares could climb 76% in the year ahead. (See RLMD stock analysis at TipRanks) Agiliti (AGTI) Well close out our look at high-potential Goldman picks with Agiliti. The company is a provider of medical equipment, offering hospitals and health systems a range of bariatrics, beds, therapy mattresses, fall prevention devices, ventilators, breast pumps, patient monitors, medical-grade adjustable chairs, and surgical equipment along with the technical support, clinical engineering, and on-site management to properly use, maintain, and adjust the myriad devices. By the numbers, Agiliti boasts over 90 service centers across the lower 48 states, supporting more than 800,000 pieces of medical equipment in over 7,000 acute care hospitals and alternate medical sites. On April 23 of this year, Agility debuted its stock on the NYSE in an IPO that was initially priced at $14. The company put over 26.3 million shares on the market, and raised approximately $431.5 million in gross proceeds in the first day of the IPO. Last week, Agiliti released its first quarterly financial report as a public company. The top line revenue, at $235 million, was 31% higher than the year-ago Q1. Net income was $9.6 million, up a strong $22.2 million from last years Q1 net loss, and EPS was 9 cents per share. Looking at the companys forward path, Goldman Sachs analyst Amit Hazan noted, While not reflected in the 1Q close balance sheet, management provided visibility to post-IPO leverage of approximately 3.3x on a pro-forma basis. While somewhat constrained from a managerial standpoint given demands from Northfield, management expects both the financial and managerial flexibility to pursue opportunistic M&A by later this year. Hazan summed up, "We view AGTIs end-to-end service model as differentiated and ideally suited in todays Hospital operating environment; we see current valuation as an attractive entry point... To this end, Hazan gives AGTI shares a Buy rating, and his $43 price target implies a 151% upside for the coming year. (To watch Hazans track record, click here) In its first few weeks on the public markets, AGTI shares have picked up 9 reviews, which include 8 Buys and just 1 Hold. The stock is selling for $17.12 and the $21.39 average price target suggests it has room for ~25% one-year upside potential. (See AGTI stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Go here to see the original:

New Forecasts: Here's What Analysts Think The Future Holds For Daqo New Energy Corp. (NYSE:DQ) - Yahoo Finance

TipRanks

Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Fridays release of economic data showing strong manufacturing activity provided a boost that pared back the market losses somewhat. The recent earnings season also gave reason for optimism the S&P listed companies, collectively, reported 46% year-over-year earnings gains in Q1, compared to the 20% expected. Goldman Sachs strategist David Kostin sees the generally positive macro data providing support for equities in an uncertain market environment. The combination of global reopening, elevated consumer savings, and strong corporate operating leverage will drive sharp recoveries in both economic and earnings growth... U.S. equities will continue to appreciate, albeit at a slower pace than has characterized the past 12 months equities will remain attractive relative to cash and bonds, Kostin noted. Taking this into consideration, our attention turned to three stocks that Goldman Sachs thinks have outsized growth prospects, with the firms analysts forecasting over 100% upside potential for each. Using TipRanks database, we found out that the rest of the Street is also on board, as each boasts a Strong Buy consensus rating. Rain Therapeutics (RAIN) Well start with a newly public biopharmaceutical company Rain Therapeutics. The company is developing a tumor-agnostic treatment strategy that selects patients based on the underlying genetics rather than the histology of the disease. Rain has two drug candidates in the pipeline, RAIN-32, which is undergoing several clinical trials, and RAD52, which is still in preclinical trial. Taking a closer look at the pipeline, we find that RAIN-32, an MDM2 inhibitor called milademetan, has a Phase 3 trial for WD/DD liposarcoma scheduled to begin in the second half of this year. At the same time, a Phase 2 trial, an MDM2 basket study, is also scheduled for 2H21. Beyond the WD/DD Phase 3 and the Phase 2 Basket study, the company is also looking to initiate another Phase 2 study in intimal sarcoma by early 2022. RAD52, the companys second pipeline candidate, is a novel approach to the treatment of breast, prostate, pancreatic, and ovarian cancers. The drug is still in early research phases, but lead candidate selection for clinical studies is set to begin sometime next year. As mentioned above, Rain is a newly public company; it held its IPO in April of this year. The company put 7,352,941 shares on the American public markets, at $17 each. The IPO raised about $125 million in gross proceeds. Opening coverage of this stock for Goldman Sachs, analyst Graig Suvannavejh writes: While were optimistic on RAIN-32s prospects in LPS, the revenue opportunity appears modest, as we project peak risk-unadj./adj. sales of $612mn/$428mn (assumes 70% POS), given just c.3K in US annual incidence. That said, our enthusiasm for RAIN also rests on RAIN-32s potential beyond LPS, including in intimal sarcoma (an ultra orphan cancer), and also MDM2-amplified solid tumors, which we see as a substantial market opportunity. Across these three, we project $2.2bn/$859mn in peak yr risk unadj./adj. sales in the US/EU5, with other future indications for RAIN-32 (trials to start in 2022) and also a preclinical RAD52 program (a synthetic lethality play) representing upside potential to our forecasts. In line with his bullish stance, Suvannavejh rates RAIN a Buy, and his $56 price target implies room for a stunning 252% upside potential in the next 12 months. (To watch Suvannavejhs track record, click here) Turning now to the rest of the Street, other analysts echo Suvannavejh's sentiment. As only Buy recommendations have been published in the last three months, RAIN earns a Strong Buy analyst consensus. With the average price target clocking in at $33.75, shares could soar 112% from current levels. (See RAIN stock analysis on TipRanks) Relmada Therapeutics (RLMD) The next stock on Goldman Sachs's radar, Relmada Therapeutics, is a clinical-stage pharmaceutical firm, which focuses on issues of the central nervous system. REL-1017, the companys prime pipeline candidate, is a novel NMDA receptor channel blocker under development as a treatment for major depressive disorder. Mental health is a major segment of the pharmaceutical industry, and the antidepressant piece of the mental health pie is expected to exceed $18.5 billion by 2027. Relmada started RELIANCE I, the first pivotal trial of REL-1017, in December of last year, testing the drug as an adjunctive treatment for major depression. By this past April, two additional studies, RELIANCE II and RELIANCE-OPS were underway. All three are now ongoing, and a fourth, Phase 1, study of REL-1017 as a monotherapy is set to begin in the first half of this year. Top-line data from the two pivotal studies is scheduled for release in 1H22. Goldman Sachs analyst Andrea Tan covers this stock, and she gives it a Buy rating along with a $78 price target that implies a 103% upside over the next 12 months. (To watch Tans track record, click here) We note a string of key events in 2021+ that could drive value inflection: (1) human abuse potential (HAP) study against positive control oxycodone in 2Q21 and ketamine in 2H21, where we see the market as pricing in too much risk of a negative outcome (see scenario analysis within); (2) topline data for monotherapy REL-1017 in 4Q21; and (3) topline pivotal data in adjunctive MDD (GSe peak sales of $2.5bn in 2033) in 1H22 with NDA submission to follow thereafter, all of which we are constructive on given the differentiated profile demonstrating rapid onset of action, enhanced efficacy, and good tolerability to-date, Tan opined. What does the rest of the Street have to say? 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $67.67 average price target, shares could climb 76% in the year ahead. (See RLMD stock analysis at TipRanks) Agiliti (AGTI) Well close out our look at high-potential Goldman picks with Agiliti. The company is a provider of medical equipment, offering hospitals and health systems a range of bariatrics, beds, therapy mattresses, fall prevention devices, ventilators, breast pumps, patient monitors, medical-grade adjustable chairs, and surgical equipment along with the technical support, clinical engineering, and on-site management to properly use, maintain, and adjust the myriad devices. By the numbers, Agiliti boasts over 90 service centers across the lower 48 states, supporting more than 800,000 pieces of medical equipment in over 7,000 acute care hospitals and alternate medical sites. On April 23 of this year, Agility debuted its stock on the NYSE in an IPO that was initially priced at $14. The company put over 26.3 million shares on the market, and raised approximately $431.5 million in gross proceeds in the first day of the IPO. Last week, Agiliti released its first quarterly financial report as a public company. The top line revenue, at $235 million, was 31% higher than the year-ago Q1. Net income was $9.6 million, up a strong $22.2 million from last years Q1 net loss, and EPS was 9 cents per share. Looking at the companys forward path, Goldman Sachs analyst Amit Hazan noted, While not reflected in the 1Q close balance sheet, management provided visibility to post-IPO leverage of approximately 3.3x on a pro-forma basis. While somewhat constrained from a managerial standpoint given demands from Northfield, management expects both the financial and managerial flexibility to pursue opportunistic M&A by later this year. Hazan summed up, "We view AGTIs end-to-end service model as differentiated and ideally suited in todays Hospital operating environment; we see current valuation as an attractive entry point... To this end, Hazan gives AGTI shares a Buy rating, and his $43 price target implies a 151% upside for the coming year. (To watch Hazans track record, click here) In its first few weeks on the public markets, AGTI shares have picked up 9 reviews, which include 8 Buys and just 1 Hold. The stock is selling for $17.12 and the $21.39 average price target suggests it has room for ~25% one-year upside potential. (See AGTI stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

See original here:

Schneider National, Inc.'s (NYSE:SNDR) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat? - Yahoo Finance

TipRanks

Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Fridays release of economic data showing strong manufacturing activity provided a boost that pared back the market losses somewhat. The recent earnings season also gave reason for optimism the S&P listed companies, collectively, reported 46% year-over-year earnings gains in Q1, compared to the 20% expected. Goldman Sachs strategist David Kostin sees the generally positive macro data providing support for equities in an uncertain market environment. The combination of global reopening, elevated consumer savings, and strong corporate operating leverage will drive sharp recoveries in both economic and earnings growth... U.S. equities will continue to appreciate, albeit at a slower pace than has characterized the past 12 months equities will remain attractive relative to cash and bonds, Kostin noted. Taking this into consideration, our attention turned to three stocks that Goldman Sachs thinks have outsized growth prospects, with the firms analysts forecasting over 100% upside potential for each. Using TipRanks database, we found out that the rest of the Street is also on board, as each boasts a Strong Buy consensus rating. Rain Therapeutics (RAIN) Well start with a newly public biopharmaceutical company Rain Therapeutics. The company is developing a tumor-agnostic treatment strategy that selects patients based on the underlying genetics rather than the histology of the disease. Rain has two drug candidates in the pipeline, RAIN-32, which is undergoing several clinical trials, and RAD52, which is still in preclinical trial. Taking a closer look at the pipeline, we find that RAIN-32, an MDM2 inhibitor called milademetan, has a Phase 3 trial for WD/DD liposarcoma scheduled to begin in the second half of this year. At the same time, a Phase 2 trial, an MDM2 basket study, is also scheduled for 2H21. Beyond the WD/DD Phase 3 and the Phase 2 Basket study, the company is also looking to initiate another Phase 2 study in intimal sarcoma by early 2022. RAD52, the companys second pipeline candidate, is a novel approach to the treatment of breast, prostate, pancreatic, and ovarian cancers. The drug is still in early research phases, but lead candidate selection for clinical studies is set to begin sometime next year. As mentioned above, Rain is a newly public company; it held its IPO in April of this year. The company put 7,352,941 shares on the American public markets, at $17 each. The IPO raised about $125 million in gross proceeds. Opening coverage of this stock for Goldman Sachs, analyst Graig Suvannavejh writes: While were optimistic on RAIN-32s prospects in LPS, the revenue opportunity appears modest, as we project peak risk-unadj./adj. sales of $612mn/$428mn (assumes 70% POS), given just c.3K in US annual incidence. That said, our enthusiasm for RAIN also rests on RAIN-32s potential beyond LPS, including in intimal sarcoma (an ultra orphan cancer), and also MDM2-amplified solid tumors, which we see as a substantial market opportunity. Across these three, we project $2.2bn/$859mn in peak yr risk unadj./adj. sales in the US/EU5, with other future indications for RAIN-32 (trials to start in 2022) and also a preclinical RAD52 program (a synthetic lethality play) representing upside potential to our forecasts. In line with his bullish stance, Suvannavejh rates RAIN a Buy, and his $56 price target implies room for a stunning 252% upside potential in the next 12 months. (To watch Suvannavejhs track record, click here) Turning now to the rest of the Street, other analysts echo Suvannavejh's sentiment. As only Buy recommendations have been published in the last three months, RAIN earns a Strong Buy analyst consensus. With the average price target clocking in at $33.75, shares could soar 112% from current levels. (See RAIN stock analysis on TipRanks) Relmada Therapeutics (RLMD) The next stock on Goldman Sachs's radar, Relmada Therapeutics, is a clinical-stage pharmaceutical firm, which focuses on issues of the central nervous system. REL-1017, the companys prime pipeline candidate, is a novel NMDA receptor channel blocker under development as a treatment for major depressive disorder. Mental health is a major segment of the pharmaceutical industry, and the antidepressant piece of the mental health pie is expected to exceed $18.5 billion by 2027. Relmada started RELIANCE I, the first pivotal trial of REL-1017, in December of last year, testing the drug as an adjunctive treatment for major depression. By this past April, two additional studies, RELIANCE II and RELIANCE-OPS were underway. All three are now ongoing, and a fourth, Phase 1, study of REL-1017 as a monotherapy is set to begin in the first half of this year. Top-line data from the two pivotal studies is scheduled for release in 1H22. Goldman Sachs analyst Andrea Tan covers this stock, and she gives it a Buy rating along with a $78 price target that implies a 103% upside over the next 12 months. (To watch Tans track record, click here) We note a string of key events in 2021+ that could drive value inflection: (1) human abuse potential (HAP) study against positive control oxycodone in 2Q21 and ketamine in 2H21, where we see the market as pricing in too much risk of a negative outcome (see scenario analysis within); (2) topline data for monotherapy REL-1017 in 4Q21; and (3) topline pivotal data in adjunctive MDD (GSe peak sales of $2.5bn in 2033) in 1H22 with NDA submission to follow thereafter, all of which we are constructive on given the differentiated profile demonstrating rapid onset of action, enhanced efficacy, and good tolerability to-date, Tan opined. What does the rest of the Street have to say? 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $67.67 average price target, shares could climb 76% in the year ahead. (See RLMD stock analysis at TipRanks) Agiliti (AGTI) Well close out our look at high-potential Goldman picks with Agiliti. The company is a provider of medical equipment, offering hospitals and health systems a range of bariatrics, beds, therapy mattresses, fall prevention devices, ventilators, breast pumps, patient monitors, medical-grade adjustable chairs, and surgical equipment along with the technical support, clinical engineering, and on-site management to properly use, maintain, and adjust the myriad devices. By the numbers, Agiliti boasts over 90 service centers across the lower 48 states, supporting more than 800,000 pieces of medical equipment in over 7,000 acute care hospitals and alternate medical sites. On April 23 of this year, Agility debuted its stock on the NYSE in an IPO that was initially priced at $14. The company put over 26.3 million shares on the market, and raised approximately $431.5 million in gross proceeds in the first day of the IPO. Last week, Agiliti released its first quarterly financial report as a public company. The top line revenue, at $235 million, was 31% higher than the year-ago Q1. Net income was $9.6 million, up a strong $22.2 million from last years Q1 net loss, and EPS was 9 cents per share. Looking at the companys forward path, Goldman Sachs analyst Amit Hazan noted, While not reflected in the 1Q close balance sheet, management provided visibility to post-IPO leverage of approximately 3.3x on a pro-forma basis. While somewhat constrained from a managerial standpoint given demands from Northfield, management expects both the financial and managerial flexibility to pursue opportunistic M&A by later this year. Hazan summed up, "We view AGTIs end-to-end service model as differentiated and ideally suited in todays Hospital operating environment; we see current valuation as an attractive entry point... To this end, Hazan gives AGTI shares a Buy rating, and his $43 price target implies a 151% upside for the coming year. (To watch Hazans track record, click here) In its first few weeks on the public markets, AGTI shares have picked up 9 reviews, which include 8 Buys and just 1 Hold. The stock is selling for $17.12 and the $21.39 average price target suggests it has room for ~25% one-year upside potential. (See AGTI stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more here:

Are Robust Financials Driving The Recent Rally In Pangaea Logistics Solutions, Ltd.'s (NASDAQ:PANL) Stock? - Yahoo Finance

TipRanks

Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Fridays release of economic data showing strong manufacturing activity provided a boost that pared back the market losses somewhat. The recent earnings season also gave reason for optimism the S&P listed companies, collectively, reported 46% year-over-year earnings gains in Q1, compared to the 20% expected. Goldman Sachs strategist David Kostin sees the generally positive macro data providing support for equities in an uncertain market environment. The combination of global reopening, elevated consumer savings, and strong corporate operating leverage will drive sharp recoveries in both economic and earnings growth... U.S. equities will continue to appreciate, albeit at a slower pace than has characterized the past 12 months equities will remain attractive relative to cash and bonds, Kostin noted. Taking this into consideration, our attention turned to three stocks that Goldman Sachs thinks have outsized growth prospects, with the firms analysts forecasting over 100% upside potential for each. Using TipRanks database, we found out that the rest of the Street is also on board, as each boasts a Strong Buy consensus rating. Rain Therapeutics (RAIN) Well start with a newly public biopharmaceutical company Rain Therapeutics. The company is developing a tumor-agnostic treatment strategy that selects patients based on the underlying genetics rather than the histology of the disease. Rain has two drug candidates in the pipeline, RAIN-32, which is undergoing several clinical trials, and RAD52, which is still in preclinical trial. Taking a closer look at the pipeline, we find that RAIN-32, an MDM2 inhibitor called milademetan, has a Phase 3 trial for WD/DD liposarcoma scheduled to begin in the second half of this year. At the same time, a Phase 2 trial, an MDM2 basket study, is also scheduled for 2H21. Beyond the WD/DD Phase 3 and the Phase 2 Basket study, the company is also looking to initiate another Phase 2 study in intimal sarcoma by early 2022. RAD52, the companys second pipeline candidate, is a novel approach to the treatment of breast, prostate, pancreatic, and ovarian cancers. The drug is still in early research phases, but lead candidate selection for clinical studies is set to begin sometime next year. As mentioned above, Rain is a newly public company; it held its IPO in April of this year. The company put 7,352,941 shares on the American public markets, at $17 each. The IPO raised about $125 million in gross proceeds. Opening coverage of this stock for Goldman Sachs, analyst Graig Suvannavejh writes: While were optimistic on RAIN-32s prospects in LPS, the revenue opportunity appears modest, as we project peak risk-unadj./adj. sales of $612mn/$428mn (assumes 70% POS), given just c.3K in US annual incidence. That said, our enthusiasm for RAIN also rests on RAIN-32s potential beyond LPS, including in intimal sarcoma (an ultra orphan cancer), and also MDM2-amplified solid tumors, which we see as a substantial market opportunity. Across these three, we project $2.2bn/$859mn in peak yr risk unadj./adj. sales in the US/EU5, with other future indications for RAIN-32 (trials to start in 2022) and also a preclinical RAD52 program (a synthetic lethality play) representing upside potential to our forecasts. In line with his bullish stance, Suvannavejh rates RAIN a Buy, and his $56 price target implies room for a stunning 252% upside potential in the next 12 months. (To watch Suvannavejhs track record, click here) Turning now to the rest of the Street, other analysts echo Suvannavejh's sentiment. As only Buy recommendations have been published in the last three months, RAIN earns a Strong Buy analyst consensus. With the average price target clocking in at $33.75, shares could soar 112% from current levels. (See RAIN stock analysis on TipRanks) Relmada Therapeutics (RLMD) The next stock on Goldman Sachs's radar, Relmada Therapeutics, is a clinical-stage pharmaceutical firm, which focuses on issues of the central nervous system. REL-1017, the companys prime pipeline candidate, is a novel NMDA receptor channel blocker under development as a treatment for major depressive disorder. Mental health is a major segment of the pharmaceutical industry, and the antidepressant piece of the mental health pie is expected to exceed $18.5 billion by 2027. Relmada started RELIANCE I, the first pivotal trial of REL-1017, in December of last year, testing the drug as an adjunctive treatment for major depression. By this past April, two additional studies, RELIANCE II and RELIANCE-OPS were underway. All three are now ongoing, and a fourth, Phase 1, study of REL-1017 as a monotherapy is set to begin in the first half of this year. Top-line data from the two pivotal studies is scheduled for release in 1H22. Goldman Sachs analyst Andrea Tan covers this stock, and she gives it a Buy rating along with a $78 price target that implies a 103% upside over the next 12 months. (To watch Tans track record, click here) We note a string of key events in 2021+ that could drive value inflection: (1) human abuse potential (HAP) study against positive control oxycodone in 2Q21 and ketamine in 2H21, where we see the market as pricing in too much risk of a negative outcome (see scenario analysis within); (2) topline data for monotherapy REL-1017 in 4Q21; and (3) topline pivotal data in adjunctive MDD (GSe peak sales of $2.5bn in 2033) in 1H22 with NDA submission to follow thereafter, all of which we are constructive on given the differentiated profile demonstrating rapid onset of action, enhanced efficacy, and good tolerability to-date, Tan opined. What does the rest of the Street have to say? 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $67.67 average price target, shares could climb 76% in the year ahead. (See RLMD stock analysis at TipRanks) Agiliti (AGTI) Well close out our look at high-potential Goldman picks with Agiliti. The company is a provider of medical equipment, offering hospitals and health systems a range of bariatrics, beds, therapy mattresses, fall prevention devices, ventilators, breast pumps, patient monitors, medical-grade adjustable chairs, and surgical equipment along with the technical support, clinical engineering, and on-site management to properly use, maintain, and adjust the myriad devices. By the numbers, Agiliti boasts over 90 service centers across the lower 48 states, supporting more than 800,000 pieces of medical equipment in over 7,000 acute care hospitals and alternate medical sites. On April 23 of this year, Agility debuted its stock on the NYSE in an IPO that was initially priced at $14. The company put over 26.3 million shares on the market, and raised approximately $431.5 million in gross proceeds in the first day of the IPO. Last week, Agiliti released its first quarterly financial report as a public company. The top line revenue, at $235 million, was 31% higher than the year-ago Q1. Net income was $9.6 million, up a strong $22.2 million from last years Q1 net loss, and EPS was 9 cents per share. Looking at the companys forward path, Goldman Sachs analyst Amit Hazan noted, While not reflected in the 1Q close balance sheet, management provided visibility to post-IPO leverage of approximately 3.3x on a pro-forma basis. While somewhat constrained from a managerial standpoint given demands from Northfield, management expects both the financial and managerial flexibility to pursue opportunistic M&A by later this year. Hazan summed up, "We view AGTIs end-to-end service model as differentiated and ideally suited in todays Hospital operating environment; we see current valuation as an attractive entry point... To this end, Hazan gives AGTI shares a Buy rating, and his $43 price target implies a 151% upside for the coming year. (To watch Hazans track record, click here) In its first few weeks on the public markets, AGTI shares have picked up 9 reviews, which include 8 Buys and just 1 Hold. The stock is selling for $17.12 and the $21.39 average price target suggests it has room for ~25% one-year upside potential. (See AGTI stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read the original post:

Google CEO: The digital divide is 'easier to bridge than most people think' - Yahoo Finance

TipRanks

Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Fridays release of economic data showing strong manufacturing activity provided a boost that pared back the market losses somewhat. The recent earnings season also gave reason for optimism the S&P listed companies, collectively, reported 46% year-over-year earnings gains in Q1, compared to the 20% expected. Goldman Sachs strategist David Kostin sees the generally positive macro data providing support for equities in an uncertain market environment. The combination of global reopening, elevated consumer savings, and strong corporate operating leverage will drive sharp recoveries in both economic and earnings growth... U.S. equities will continue to appreciate, albeit at a slower pace than has characterized the past 12 months equities will remain attractive relative to cash and bonds, Kostin noted. Taking this into consideration, our attention turned to three stocks that Goldman Sachs thinks have outsized growth prospects, with the firms analysts forecasting over 100% upside potential for each. Using TipRanks database, we found out that the rest of the Street is also on board, as each boasts a Strong Buy consensus rating. Rain Therapeutics (RAIN) Well start with a newly public biopharmaceutical company Rain Therapeutics. The company is developing a tumor-agnostic treatment strategy that selects patients based on the underlying genetics rather than the histology of the disease. Rain has two drug candidates in the pipeline, RAIN-32, which is undergoing several clinical trials, and RAD52, which is still in preclinical trial. Taking a closer look at the pipeline, we find that RAIN-32, an MDM2 inhibitor called milademetan, has a Phase 3 trial for WD/DD liposarcoma scheduled to begin in the second half of this year. At the same time, a Phase 2 trial, an MDM2 basket study, is also scheduled for 2H21. Beyond the WD/DD Phase 3 and the Phase 2 Basket study, the company is also looking to initiate another Phase 2 study in intimal sarcoma by early 2022. RAD52, the companys second pipeline candidate, is a novel approach to the treatment of breast, prostate, pancreatic, and ovarian cancers. The drug is still in early research phases, but lead candidate selection for clinical studies is set to begin sometime next year. As mentioned above, Rain is a newly public company; it held its IPO in April of this year. The company put 7,352,941 shares on the American public markets, at $17 each. The IPO raised about $125 million in gross proceeds. Opening coverage of this stock for Goldman Sachs, analyst Graig Suvannavejh writes: While were optimistic on RAIN-32s prospects in LPS, the revenue opportunity appears modest, as we project peak risk-unadj./adj. sales of $612mn/$428mn (assumes 70% POS), given just c.3K in US annual incidence. That said, our enthusiasm for RAIN also rests on RAIN-32s potential beyond LPS, including in intimal sarcoma (an ultra orphan cancer), and also MDM2-amplified solid tumors, which we see as a substantial market opportunity. Across these three, we project $2.2bn/$859mn in peak yr risk unadj./adj. sales in the US/EU5, with other future indications for RAIN-32 (trials to start in 2022) and also a preclinical RAD52 program (a synthetic lethality play) representing upside potential to our forecasts. In line with his bullish stance, Suvannavejh rates RAIN a Buy, and his $56 price target implies room for a stunning 252% upside potential in the next 12 months. (To watch Suvannavejhs track record, click here) Turning now to the rest of the Street, other analysts echo Suvannavejh's sentiment. As only Buy recommendations have been published in the last three months, RAIN earns a Strong Buy analyst consensus. With the average price target clocking in at $33.75, shares could soar 112% from current levels. (See RAIN stock analysis on TipRanks) Relmada Therapeutics (RLMD) The next stock on Goldman Sachs's radar, Relmada Therapeutics, is a clinical-stage pharmaceutical firm, which focuses on issues of the central nervous system. REL-1017, the companys prime pipeline candidate, is a novel NMDA receptor channel blocker under development as a treatment for major depressive disorder. Mental health is a major segment of the pharmaceutical industry, and the antidepressant piece of the mental health pie is expected to exceed $18.5 billion by 2027. Relmada started RELIANCE I, the first pivotal trial of REL-1017, in December of last year, testing the drug as an adjunctive treatment for major depression. By this past April, two additional studies, RELIANCE II and RELIANCE-OPS were underway. All three are now ongoing, and a fourth, Phase 1, study of REL-1017 as a monotherapy is set to begin in the first half of this year. Top-line data from the two pivotal studies is scheduled for release in 1H22. Goldman Sachs analyst Andrea Tan covers this stock, and she gives it a Buy rating along with a $78 price target that implies a 103% upside over the next 12 months. (To watch Tans track record, click here) We note a string of key events in 2021+ that could drive value inflection: (1) human abuse potential (HAP) study against positive control oxycodone in 2Q21 and ketamine in 2H21, where we see the market as pricing in too much risk of a negative outcome (see scenario analysis within); (2) topline data for monotherapy REL-1017 in 4Q21; and (3) topline pivotal data in adjunctive MDD (GSe peak sales of $2.5bn in 2033) in 1H22 with NDA submission to follow thereafter, all of which we are constructive on given the differentiated profile demonstrating rapid onset of action, enhanced efficacy, and good tolerability to-date, Tan opined. What does the rest of the Street have to say? 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $67.67 average price target, shares could climb 76% in the year ahead. (See RLMD stock analysis at TipRanks) Agiliti (AGTI) Well close out our look at high-potential Goldman picks with Agiliti. The company is a provider of medical equipment, offering hospitals and health systems a range of bariatrics, beds, therapy mattresses, fall prevention devices, ventilators, breast pumps, patient monitors, medical-grade adjustable chairs, and surgical equipment along with the technical support, clinical engineering, and on-site management to properly use, maintain, and adjust the myriad devices. By the numbers, Agiliti boasts over 90 service centers across the lower 48 states, supporting more than 800,000 pieces of medical equipment in over 7,000 acute care hospitals and alternate medical sites. On April 23 of this year, Agility debuted its stock on the NYSE in an IPO that was initially priced at $14. The company put over 26.3 million shares on the market, and raised approximately $431.5 million in gross proceeds in the first day of the IPO. Last week, Agiliti released its first quarterly financial report as a public company. The top line revenue, at $235 million, was 31% higher than the year-ago Q1. Net income was $9.6 million, up a strong $22.2 million from last years Q1 net loss, and EPS was 9 cents per share. Looking at the companys forward path, Goldman Sachs analyst Amit Hazan noted, While not reflected in the 1Q close balance sheet, management provided visibility to post-IPO leverage of approximately 3.3x on a pro-forma basis. While somewhat constrained from a managerial standpoint given demands from Northfield, management expects both the financial and managerial flexibility to pursue opportunistic M&A by later this year. Hazan summed up, "We view AGTIs end-to-end service model as differentiated and ideally suited in todays Hospital operating environment; we see current valuation as an attractive entry point... To this end, Hazan gives AGTI shares a Buy rating, and his $43 price target implies a 151% upside for the coming year. (To watch Hazans track record, click here) In its first few weeks on the public markets, AGTI shares have picked up 9 reviews, which include 8 Buys and just 1 Hold. The stock is selling for $17.12 and the $21.39 average price target suggests it has room for ~25% one-year upside potential. (See AGTI stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

More:

RISE Education Cayman's (NASDAQ:REDU) Stock Price Has Reduced 77% In The Past Three Years - Yahoo Finance

The NBA on Monday announced the creation of NBA Africa, where it will hold standalone business operations and has lured many NBA figures as investors in the venture.

The NBA has business relationships in other continents, so extending it to Africa where its relationship began in 1993 with a trip to the continent spearheaded by late commissioner David Stern seems like a logical move.

Some of its notable NBA investors include Grant Hill, Dikembe Mutombo, Junior Bridgeman, Joakim Noah and Luol Deng.

NBA commissioner Adam Silver, in an early morning news conference, estimated the enterprise value for NBA Africa is worth nearly $1 billion.

Africa is a growing market globally, and the NBAs relationship has grown in recent years, illustrated by the new 12-team Basketball Africa League. Victor Williams, NBA Africa CEO, believes basketball will become a main footprint in Africa within the next 10 years.

In order to reach that milestone, we've developed a comprehensive growth plan that will greatly accelerate the development of Africa's basketball ecosystem, deepen our fan engagement efforts, advanced social responsibility, and drive economic growth, Williams said.

The future of Africa is bright. And we will continue to use the game to shine a spotlight on Africa's capacity to be a global leader.

NBA commissioner Adam Silver, in an early morning news conference, estimated the enterprise value for NBA Africa is worth nearly $1 billion. (Cyril Ndegeya/Xinhua via Getty Images)

Silver and Deputy Commissioner Mark Tatum will serve, among others, on the NBA Africa board of directors.

African investors include Nigerian Babatunde "Tunde" Folawiyo, Chairman and CEO of Yinka Folawiyo Group and Helios Fairfax Partners Corporation, led by Nigerian Tope Lawani, co-CEO of HFP and co-founder and managing partner of Helios Investment Partners.

The groups wide range of experiences in the business world should help NBA Africas growth as it aims to establish content, gain media rights and build corporate sponsorships very similar to the NBAs relationship with China.

Lawani recalls watching the 1994 NBA Finals on his small television when Nigerian-born Hakeem Olajuwon led the Houston Rockets to the first of two straight championships.

Story continues

I was proud to be Nigerian, proud to be African, Lawani said.

Silver pointed out the 55 NBA players who are from Africa or have one or both parents who are African. One player who was on that trip with commissioner Stern in 1993 was Mutombo, a native of Congo.

Mutombo has been very invested in hospitals in Congo, and met former South African president Nelson Mandela on that trip.

Africa is one of the youngest population in the world. And Africa youth have just need the opportunity and the support to achieve great things, Mutombo said. The new NBA Africa is that transformative next step, to do just that: giving more African youth the same opportunity that I had many years ago.

More from Yahoo Sports:

Continue reading here:

NBA announces formation of NBA Africa as the sport expands on the continent - Yahoo Sports

One of the nation's leading epidemiologists has called on the government to do more to convince young Australians to take the Covid-19 vaccine when it becomes available to them.

UNSW Professor Mary-Louise McLaws, who is a World Health Organisation advisor, said it was vital more was done to convince people aged between 20 and 30 to come forward for the vaccine amid waning public support for inoculation after the emergence of rare blood clotting complications with the AstraZeneca jab.

"We should be talking about how do we get the 20 and 30-year-olds vaccinated because they represent up to 40 per cent of all cases last year," she told ABC Breakfast on Monday.

She said the age group needs to be motivated to take the jab, and should be told "they are heroes" by doing so.

"They are going to save us and that is true," Prof McLaws said.

She said it was vital fear surrounding the vaccine was dispelled and mixed-messaging around their safety needed to stop.

"Every vaccine does have some risk, but it is so small compared to the risk for the 20-39 -year-olds acquiring COVID-19 and spreading it," Prof McLaws said.

Mary-Louise McLaws says young Australian adults will play a key role in how successful the vaccine rollout is. Source: Getty

"So we need to tell them that we are forever grateful for what they going to do for the country."

Experts have continuously warned Australia will only be able to open its borders once herd immunity is achieved.

According to a recent paper published by UNSW epidemiologist Professor Raina MacIntyre, 75 per cent of a population would need to be vaccinated for a vaccine with 80 per cent efficacy to achieve herd immunity.

An entire population would need to be vaccinated if efficacy is as low as 60 per cent.

Recent research has indicated the AstraZeneca is less effective than the Pfizer and Moderna jabs.

Story continues

Recent Public Health England research found the Pfizer jab was 88 per cent effective at stopping symptomatic disease from the now dominant Indian strain in the UK, while the AstraZeneca was much lower at 60 per cent.

The Australian Technical Advisory Group on Immunisation (ATAGI) recommends the Pfizer jab over AstraZeneca jab for adults aged under 50 years due to the rare blood clotting side-effects.

Yet Australia's vaccine rollout has been plagued by complications and has fallen significantly behind schedule.

About 3.6 million doses of coronavirus vaccines have so far been administered, through a mix of AstraZeneca and Pfizer jabs well behind the targets previously set.

However the government is now promising two million doses of Pfizer will arrive in Australia each week from the start of October.

The Department of Health had previously promised all adults will have been offered a jab by the same month.

The latest pledge could see every Australian who wants protection from COVID-19 could be fully immunised by the end of this year.

Physician Dr Norman Swan, the face of the ABC's coronavirus coverage, said the government was "dreaming". He predicted it will be well into 2022 when all adults will have been offered a vaccine.

Finance Minister Simon Birmingham said the significantly increased doses was the government's hope but stopped short of making a firm commitment.

"There have been many uncertainties in the vaccine rollout to date and we need to continue to be honest about the fact we can't control every aspect of global supply," he said.

"We can't control whether there are unexpected impacts in relation to health or other factors or advice that impact the vaccine rollout."

Do you have a story tip? Email: newsroomau@yahoonews.com

You can also follow us on Facebook, Instagram and Twitter and download the Yahoo News app from the App Store or Google Play.

Original post:

The surprising age group that will save Australia from Covid-19 - Yahoo News Australia

TipRanks

Take a good look at the headlines, and youll be excused for thinking that were back in 1979. The late Carter years are remembered as the time of stagflation: high inflation, high unemployment, fuel shortages, and a general malaise. So far, weve seen fuel shortages and gas station lines across the Southeast, rising commodity and housing prices, and unemployment ticking up even as the number of job openings increases. Weighing in from investment firm Goldman Sachs, chief economist Jan Hatzius believes that the current worrisome numbers are a short-term phenomenon. I think that its quite plausible that employers may be prioritizing post-pandemic hiring over seasonal hiring to some degree that then shows up as weaker numbers. Thats still going to be with us, I think, for the next couple of months. But the flip side should be stronger job growth numbers than we previously thought later in the year," Hatzius noted. Turning to inflation, Hatzius again outlines a better picture for the long-term: Ultimately, its going to be more temporary. A lot of the drivers of inflation, not just the commodity numbers, but also things like the base effect and some of the impact of reopening on service prices a lot of that is pretty short-term. It doesnt really tell you a lot of inflation in 2022 when we think well probably be back to about 2% for core PCE. Sometimes, the market pros will go out on a limb and take a position that is clearly an outlier compared to the consensus. Thats what Hatzius is doing here, and his colleagues have his back. Using the TipRanks database, weve found three stocks that Goldmans analysts have picked out for 50% or better gains. Here are the details. Vivint Smart Home (VVNT) Well start with an interesting take on the internet of things, the smart home niche. Vivint Smart Home is a leader in this industry, delivering home security systems and home automation, services that include security cameras, doorbell cameras, and outdoor grounds cameras. Vivint boasts over 1.5 million customers in North America. This month, Vivint has seen both good and bad news. On May 3, the company settled a court action with the US Department of Justice and the Federal Trade Commission, accepting a $20 million fine for alleged violations of the Fair Credit Reporting Act. On the positive side, the company reported solid year-over-year gains in its 1Q21 financial release. Vivant showed a 13.2% yoy gain in revenues, to $343.3 million, driving by a 20.1% increase in new subscribers. The total number of new subscribers, 60,127, was a company record for Q1. Looking ahead, Vivint gave upbeat forward guidance, predicting 2021 revenue in the range of $1.38 to $1.42 billion, and a year-end total of 1.8 to 1.85 million subscribers. For Goldman Sachs analyst Rod Hall, all of this adds up to reason for an upgrade. Hall bumped his stance on VVNT from Neutral to Buy, and set his price target at $24, suggesting an impressive one-year upside of 81%. (To watch Halls track record, click here) We believe Vivints consumer financing partnerships position the company for sustained positive cash-flow driven by reduced upfront subscriber acquisition cost outlays. We also see valuation as attractive at current levels with a reverse DCF suggesting unlikely negative terminal growth assumptions embedded in the current stock price. Further, we see a potential entry into the insurance business as an option on additional value, Hall explained. Overall, VVNT has received 4 recent analyst reviews, breaking down to 3 Buys versus 1 Hold and making the analyst consensus rating a Strong Buy. The stock has current trading price of $23.20 and an average price target of $13.07, indicating ~75% upside potential for the next 12 months. (See VVNT stock analysis on TipRanks) DoubleVerify Holdings (DV) The digital world has transformed the advertising and marketing industries but along with that, has come issues in trust. DoubleVerify, a newly public company, is in the business of ensuring safety in the world of online advertising. The company offers a software platform for measurement and analytics in digital media, providing marketers with secure and accurate data to track campaigns and results. The goal: greater confidence in branding and customer reach. DoubleVerify has been in the digital ad business for over a decade, and just last month, it went public. The IPO was initially priced at $27 per share, but it opened at $35 and closed its first days trading at $36. Overall, the offering of 15.333 million shares was comprised of 9.977 million put on the market by the company and 5.355 million shares sold by existing stockholders. DV raised over $350 million in the offering, before expenses. Analyst Christopher Merwin initiated coverage of this stock for Goldman Sachs, and was impressed with what he saw. DoubleVerify grew revenue 75% y/y in 2019 and 34% y/y in 2020. 2019 strength was driven by new product introduction, deepening integrations with major demand side platforms including The Trade Desk, Google and Amazon, as well competitive share gains. Given DoubleVerifys transaction based revenue model, the company is dependent on sustained growth of the overall digital ad ecosystem," Merwin noted. The analyst added, "We estimate a total of ~141 trillion ad impressions across various digital channels as of 2020, growing to~184 trillion by 2023. Based on DVs current transaction fee ranging from 6-9 cents per1,000 impressions, we estimate an overall TAM of $10bnn, growing to ~$14bnn by FY23..." In line with his bullish stance, Merwin rates DV a Buy, and his $47 price target implies room for a 57% upside potential in the next 12 months. (To watch Merwins track record, click here) This newly public stock has attracted plenty of attention in its first few weeks on the markets; no fewer than 11 analysts have weighed in, and their opinions break down 8 to 3 in favor of the Buys versus the Holds, for a Moderate Buy consensus rating. DV shares are currently trading for $29.92 and have an average price target of $39, giving the stock a 30% one-year upside potential. (See DV stock analysis on TipRanks) Zymergen (ZY) Well wrap up with a company that has take a unique approach to the green economy. Zymergen describes itself as a biofacturing company, which creates new modes of manufacturing a wide range of products, from electronics, to personal care and hygiene, to agricultural technology all with an eye toward both using and protecting the natural world. Zymergen took its business public in April, holding its IPO on the 22 of that month. The firm raised over $500 million and put over 18.5 million shares into circulation. The companys IPO took place just four months after the public launch of the companys first commercial product, Hyaline, a polymer film for use in electronic displays. Covering the stock for Goldman Sachs, analyst Matthew Sykes writes of the companys potential: The key to the equity story for ZY is first to validate their synthetic biology development and platform through the successful commercial launch and shipments of their first product Hyaline in Q1 of 2022. Subsequently, ZY will need to follow-on with additional products in the electronic films space effectively demonstrating the speed and scale at which they can develop and roll-out products faster and cheaper than those made through the traditional, petrochemical process. Demonstrating the value of the platform and diversifying their revenue base across multiple product lines and end markets will be key to establishing the sustainability and competitive advantages of the business model. Sykes clearly sees Zymergen as capable of meeting that potential, and gives the stock a Buy rating with a $55 price target to suggest an upside of 52% in the next 12 months. (To watch Sykes track record, click here) Sometimes, a new stock hits all the right buttons and Zymergen has done that for Wall Streets analysts. The consensus here is unanimous, with 5 positive reviews backing a Strong Buy rating. The $48.50 average price target implies ~33% upside from the $36.59 trading price. (See Zymergen stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

See more here:

Elon Musks carbon comments will be changing point for bitcoin: Gryphon CEO - Yahoo Finance

Despite increased vaccinations and easing coronavirus restrictions, the U.S. economy is experiencing a labor crunch that's prompting a number of companies to hike wages, in part to attract needed workers.

The strong COVID-19 rebound has lit a fire under the economy, but April's weak jobs figures stoked a furious debate about whether enhanced unemployment benefits were behind the worker shortage. As a result, a handful of states like Mississippi, Missouri, Montana, and South Carolina, have moved to end federal job aid early.

In the last few weeks, big-name retailers and corporations are upping wages and adding lucrative incentives in a bid to attract workers. In the meantime, Congress continues to fight over a $15 per hour federal minimum wage, in a sign of how worker wages continues to be a policy flashpoint.

ATHENS, GREECE - 2021/04/21: A man walking past the Under Armour store at Syntagma square. (Photo by Nikolas Joao Kokovlis/SOPA Images/LightRocket via Getty Images)

Under Armour revealed that it would raise the minimum wage for over 8,000 hourly employees to $15 in the U.S. and C$15.25 ($12.59) in Canada.

"We are committed to doing the right thing, and at the center of our commitment is ensuring our teammates feel valued and appreciated," Under Armour CEO Patrik Frisk said in a statement on Wednesday.

The changes are set to roll out starting June 6.

A man walks near a Bank of America branch in New York's Times Square Decemeber 11, 2008. Bank of America Corp said on Thursday it plans to eliminate 30,000 to 35,000 jobs over three years as it integrates Merrill Lynch & Co and experiences weaker business activity amid the economic recession. REUTERS/Brendan McDermid (UNITED STATES)

Bank of America (BAC) announced on Tuesday it was boosting its minimum wage to $26 an hour by 2025, according to Chief Executive Officer Brian Moynihan.

This is not the first time the big bank has raised wages. In 2017, Bank of America hiked its minimum wage to $15 an hour. Just two years later, it said it will guarantee a $20 hourly wage over the next two years.

The bank hit that goal in 2020 one year earlier than expected.

Fast-food workers and their supporters join a nationwide protest for higher wages and union rights outside McDonald's in Los Angeles, California, United States, November 10, 2015. REUTERS/Lucy Nicholson

The Golden Arches (MCD) recently announced that it will raise hourly wages "by an average of 10%" for more than 36,500 employees at more than 660 U.S. restaurants.

"These increases, which have already begun, will be rolled out over the next several months and include shifting the entry level range for crew to at least $11-$17 an hour," the fast food giant said in a statement adding that shift managers would be paid at least $15 an hour.

Story continues

The wage increases will not apply to employees at the fast food giant's 13,000+ franchise locations.

A Chipotle worker makes the new Quesadilla dish at the Chipotle Next Kitchen in Manhattan, New York, U.S., June 28, 2018. REUTERS/Shannon Stapleton

Chipotle (CMG) said it would lift the average hourly wage for its restaurant workers to $15 an hour, in addition to offering employee referral bonuses of $200 for restaurant workers and $750 for general managers.

The company highlighted a track for new hires to become managers at several locations within four years the position, dubbed a 'restaurateur,' pays $100,000 a year.

Employee Stanaleen Greenman works on processing packages kicked out by the automated scanning and labeling system at the Amazon fulfillment center in Kent, Washington, U.S., October 24, 2018. REUTERS/Lindsey Wasson

The tech giant (AMZN) revealed it would be hiring 75,000 employees across its fulfillment and transportation sectors, with average pay starting at over $17 per hour.

The retail giant touted sign-on bonuses of up to $1,000, in addition to "industry-leading benefits, which include health, vision, and dental insurance, 401(k) with 50% company match, paid parental leave, and access to various company-funded upskilling opportunities, includingAmazons innovative Career Choice program, which prepays 95% of tuition for courses in high-demand fields."

Other retailers such as Best Buy, Costco, Signet and Starbucks have signaled their support for wage hikes over the past year with many committing to hourly increases at $15 or above.

April's unemployment rate unexpectedly increased to 6.1% with only 266,000 jobs added. Bloomberg consensus estimates had expected an increase of 1 million jobs with a dip in the unemployment rate at 5.8%

The disappointing jobs report "could indicate that labor shortages are becoming a significant drag," Michael Pearce, senior U.S. economist for Capital Economics, wrote in a recent note.

Alexandra is a Producer & Entertainment Correspondent at Yahoo Finance. Follow her on Twitter @alliecanal8193

Read more:

See original here:

From Amazon to McDonald's, here's who's hiking wages amid the labor crunch - Yahoo Finance

Jayson Tatum saved an otherwise ugly start to the NBA's play-in tournament experiment.

The 23-year-old Boston Celtics forward staked his claim to superstardom in Tuesday's nightcap, scoring 50 points in a 118-100 win to send the Washington Wizards to an elimination game against the Indiana Pacers on Thursday. Tatum made fellow All-Stars Bradley Beal and Russell Westbrook look like the junior varsity.

"Be the best player on the floor. That's what I told myself coming into this game," Tatum told TNT's national broadcast after his third 50-point game in 39 days set a high bar for the play-in record. "Do whatever it takes to win and be the best player on the floor. I felt like, if I did that, we'd have a good chance to win."

The Celtics advanced as a seventh seed to face Kevin Durant, James Harden and old friend Kyrie Irving's second-seeded Brooklyn Nets in the first round of the Eastern Conference playoffs. Game 1 is Saturday.

Tatum scored 23 of his 50 in the third quarter, punishing the Wizards at every level. Step-back 3's. Stop-and-pop 15-footers. Finger-roll layups. You name the move, Tatum had it in his bag, and Washington had no answer. A 17-2 run to open the second half was all the Celtics needed to put the Wizards to sleep.

And Tatum was the only reason for anyone to stay up.

Boston Celtics star Jayson Tatum scored 50 points for the third time in just over a month. (Maddie Malhotra/Getty Images)

The night began with an elimination game between two depleted sub-.500 teams battling for the right to (probably) lose to the Wizards on Thursday. The ninth-place Indiana Pacers, playing without starters Caris LeVert (COVID-19 health and safety protocols) and Myles Turner (turf toe), led by as many as 39 points in a blowout of a 10th-place Charlotte Hornets team that was without its best player, Gordon Hayward (foot).

The entire second half was garbage time. The final minutes pitted the immortal Amidah Brimah against Hornets legend Nate Darling. The two had combined for 55 minutes all season. It was painful to watch.

Story continues

If opening night of the play-in tournament is an indication of what's to come in the playoffs, the NBA is in for some trouble. The league better hope these teams are lambs to the slaughter once the real games begin, because it looked like the walking wounded out there. Who could blame them after a condensed regular season started two months from the end of last year's Finals earlier than anyone anticipated.

"We've been through a lot," said Celtics coach Brad Stevens, "so we're hardened in a lot of ways. We've been backs-against-the-wall most of the year, and to have to play tonight to get into the playoffs, just to earn the right to play probably the most talented team that's been assembled since I've been in the NBA, it takes a lot of effort. It takes a lot of togetherness, and it takes staying together through tougher times."

Few teams have avoided the toll taken by this arduous season. It was in plain view on Tuesday.

COVID-19 claimed LeVert as the first protocol absence of what is sure to be more in the weeks to come. Soft tissue injuries sidelined starters Hayward, Turner and Boston's Jaylen Brown. Charlotte's Rookie of the Year favorite, LaMelo Ball, nursed his injured right wrist during pregame warmups. He was a -35 and shot 4 for 14 from the field. Beal was seen stretching his strained left hamstring on the sidelines during a subpar performance. Celtics starters Marcus Smart and Robert Williams both limped off the court in the second quarter. Smart returned in diminished capacity. Williams started the second half, only to exit a minute later.

After the Celtics laid waste to the Wizards, TNT play-by-play announcer Marv Albert openly wondered whether Westbrook was feeling well, because the former MVP shot 6-for-18 from the field and committed four turnovers. He looked exhausted from chasing the triple-double record, and he never looks exhausted.

The Pacers made 16 of their 35 (45.7%) 3-point attempts. The other three teams combined to shoot 30 for 106 (28.3%) from deep. The Celtics' 39.6 field-goal percentage was their worst in a victory all season, and they won by 18. The Wizards committed 31 fouls. Their entire frontcourt rotation was in trouble by halftime. These are signs of tired teams. The Hornets played like their reservations for Cancun expired at midnight.

Maybe hosting a play-in tournament in this season of all seasons wasn't such a great idea, after all. Thank goodness for Tatum, at least, and here's hoping Lakers-Warriors on Wednesday is a lot more entertaining.

Ben Rohrbach is a staff writer for Yahoo Sports. Have a tip? Email him at rohrbach_ben@yahoo.com or follow him on Twitter! Follow @brohrbach

More from Yahoo Sports:

Here is the original post:

Jayson Tatum's 50 points the lone bright spot in a rough start to the NBA play-in tournament - Yahoo Sports